Volumetric

zPREDICTA is developing organ-specific, physiologically-relevant 3D cell culture models providing a 1-to-1 reconstruction of human tissues. This is the only available 3D culture approach that comprehensively accounts for the major components of the cellular and extracellular tissue microenvironment preserving the critical interactions between a tumor and its surroundings. Clinical study data demonstrate the high correlation between drug efficacy measured in our platform and the clinical response

shared extracted concept terms: approach; shared product terms: tissue, human, drug, organ; shared product theme: health and clinical care; shared affiliation: Y Combinator

Rosebud Biosciences accelerates drug development by screening drugs against organoids (micro-organs) that have the same gene mutations as the patients. We partner with therapeutics companies to screen their drugs, and we perform our own drug discovery for rare diseases that have no existing treatments. Our organoids are also fetal-like and enable discovery of novel drug targets for pediatric diseases. This technology was validated at Stanford, published in a prestigious journal, and has already

shared product terms: drug, development, screen, organ; shared product theme: context and memory, health and clinical care; same category: Healthcare; shared affiliation: Y Combinator

Perlara 1.0 (Feb 2014 - Feb 2019) launched early R&D joint ventures called PerlQuests with highly motivated rare disease families, companies or impact investors. We screened gene-edited patient avatars for repurposable drugs in order to build a predictive R&D engine called ArkBase. We planned to monetize programs based on ArkBase predictions by selectively spinning out asset-centric clinical development NewCos. Perlara 1.5 (March 2019 - April 2020) was the transition to a one-person virtual clin

shared product terms: screen, patient, drug, out; shared product theme: context and memory, health and clinical care; same category: Healthcare; shared affiliation: Y Combinator

Your immune system is your body’s best weapon and defense against cancer. It is only when it is overcome that cancer develops into full blown disease. Dendritic cells sit at the helm of the immune system, directing and dictating immune responses. Data has shown dendritic cells are often dysfunctional in cancer patients, and that this dysfunction is a bottleneck for other therapies. Guardian Bio’s approach is focused on creating a dendritic cell-based product which drives anti-tumor activity thro

shared product terms: body, full, cell, patient; shared product theme: health and clinical care; shared affiliation: Y Combinator

In a nutshell: many diseases are caused by how much your cells squeeze (asthma, fibrosis, others). We discover drugs that control how much cells squeeze, with ease, to treat disease. We use patented bioMEMS technology to turn cell strength (cells' ability to pull/ squeeze) into a quantifiable metric in drug discovery, to help find better drugs for mechanical diseases. We screen 100,000s of drugs against numerous contractile human cell types to comprehensively map human mechanobiology (the "contr

shared product terms: cell, drug, screen, human; shared product theme: context and memory; same category: Healthcare; shared affiliation: Y Combinator

Patient-controlled feeding tube that can trigger the body's own powerful appetite-suppressing hormones, including GLP-1, without drugs or surgery.

shared product terms: patient, body, own, drug; shared product theme: health and clinical care; same category: Healthcare